RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13, 330

Shiwei Zhou; Obinna N Obianom; Jiangsheng Huang; Dong Guo; Hong Yang; Qing Li; Yan Shu

doi:10.3390/pharmaceutics15061623

RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation. Pharmaceutics 2021, 13, 330

Pharmaceutics. 2023 May 30;15(6):1623. doi: 10.3390/pharmaceutics15061623.

Authors

Shiwei Zhou^{1

2

3}, Obinna N Obianom², Jiangsheng Huang³, Dong Guo², Hong Yang², Qing Li¹, Yan Shu^{1

2}

Affiliations

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
² Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
³ Department of Thyroid Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Abstract

The authors and the journal retract the article, 'Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation' [...].

Publication types

Retraction Notice